tetano
Editor, Senior Moderator
Eurosurveillance, Volume 20, Issue 24, 18 June 2015
Review articles
Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children
J Li-Kim-Moy (
)[SUP]1[/SUP][SUP],2[/SUP], J K Yin[SUP]1[/SUP][SUP],2[/SUP], H Rashid[SUP]1[/SUP], G Khandaker[SUP]1[/SUP][SUP],2[/SUP][SUP],3[/SUP], C King[SUP]1[/SUP][SUP],2[/SUP], N Wood[SUP]1[/SUP][SUP],2[/SUP], K K Macartney[SUP]1[/SUP][SUP],2[/SUP][SUP],4[/SUP], C Jones[SUP]2[/SUP][SUP],3[/SUP][SUP],4[/SUP][SUP],5[/SUP], R Booy[SUP]1[/SUP][SUP],2[/SUP][SUP],4[/SUP][SUP],5[/SUP]
Citation style for this article: Li-Kim-Moy J, Yin JK, Rashid H, Khandaker G, King C, Wood N, Macartney KK, Jones C, Booy R. Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children. Euro Surveill. 2015;20(24)
ii=21159. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21159
Date of submission: 22 May 2014
[SIZE=+0]In 2010, increased febrile convulsions (FC) occurred after administration of inactivated trivalent influenza vaccine (TIV) in Australia. We systematically reviewed the rates of fever, FC and serious adverse events (SAEs) after TIV, focussing on published and unpublished clinical trial data from 2005 to 2012, and performed meta-analysis of fever rates. From 4,372 records in electronic databases, 18 randomised controlled trials (RCTs), 14 non-randomised clinical trials, six observational studies and 12 registered trials (five RCTs and seven non-randomised) were identified. In published RCTs, fever ≥ 38 ?C rates after first dose of non-adjuvanted TIV were 6.7% and 6.9% for children aged 6?35 months and ≥ 3 years, respectively. Analysis of RCTs by vaccine manufacturer showed pooled fever estimates up to 5.1% with Sanofi or GlaxoSmithKline vaccines; bioCSL vaccines were used in two non-randomised clinical trials and one unpublished RCT and were associated with fever in 22.5?37.1% for children aged 6?35 months. In RCTs, FCs occurred at a rate of 1.1 per 1,000 vaccinated children. While most TIVs induced acceptably low fever rates, bioCSL influenza vaccines were associated with much higher rates of fever in young children. Future standardised study methodology and access to individual level data would be illuminating.
full article[/SIZE]
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21159
Review articles
Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children
J Li-Kim-Moy (
- National Centre for Immunisation Research and Surveillance, The Children?s Hospital at Westmead, New South Wales, Australia
- Sydney Medical School, The University of Sydney, New South Wales, Australia
- Centre for Perinatal Infection Research, The Children?s Hospital at Westmead, New South Wales, Australia
- Department of Microbiology and Infectious Diseases, The Children?s Hospital at Westmead, New South Wales, Australia
- Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, New South Wales, Australia
Citation style for this article: Li-Kim-Moy J, Yin JK, Rashid H, Khandaker G, King C, Wood N, Macartney KK, Jones C, Booy R. Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children. Euro Surveill. 2015;20(24)
ii=21159. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21159Date of submission: 22 May 2014
[SIZE=+0]In 2010, increased febrile convulsions (FC) occurred after administration of inactivated trivalent influenza vaccine (TIV) in Australia. We systematically reviewed the rates of fever, FC and serious adverse events (SAEs) after TIV, focussing on published and unpublished clinical trial data from 2005 to 2012, and performed meta-analysis of fever rates. From 4,372 records in electronic databases, 18 randomised controlled trials (RCTs), 14 non-randomised clinical trials, six observational studies and 12 registered trials (five RCTs and seven non-randomised) were identified. In published RCTs, fever ≥ 38 ?C rates after first dose of non-adjuvanted TIV were 6.7% and 6.9% for children aged 6?35 months and ≥ 3 years, respectively. Analysis of RCTs by vaccine manufacturer showed pooled fever estimates up to 5.1% with Sanofi or GlaxoSmithKline vaccines; bioCSL vaccines were used in two non-randomised clinical trials and one unpublished RCT and were associated with fever in 22.5?37.1% for children aged 6?35 months. In RCTs, FCs occurred at a rate of 1.1 per 1,000 vaccinated children. While most TIVs induced acceptably low fever rates, bioCSL influenza vaccines were associated with much higher rates of fever in young children. Future standardised study methodology and access to individual level data would be illuminating.
full article[/SIZE]
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21159